IRCT201111022704N2已完成2 期
The efficacy of rituximab for recalcitrant Pemphigus Vulgaris in the reduction of prednisolone dose
Vice-chancellor for Research of Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Patients with Pemphigus Vulgaris who are candidates for rituximab (failure to respond or frequent recurrences under long-term (months to years) oral corticosteroids more than 10 mg daily with or without additional immunosuppressive therapy? or oral corticosteroids intolerance with or without short and long-term oral coricosteroids side effects)
- •Exclusion criterion were: pregnancy and breast feeding?history of sensitization to murine protein?hepatitis B cariers?cardiac arrhythmias & angina pectoris?high tumor burden?active infections
排除标准
- 未提供
研究者
相似试验
未知
2 期
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
已完成
不适用
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
已完成
不适用
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20
进行中（未招募）
1 期
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300